Panama7/iStock Editorial via Getty Images
- Sanofi (SNY) to acquire Dynavax Technologies (DVAX) for $15.50 per share in cash, valuing the company at approximately $2.2 billion—a 39% premium to its December 23 closing price.
- This deal adds Dynavax’s marketed HEPLISAV-B adult hepatitis B vaccine and
Follow us on Google for the latest stock news